ERBB2 is altered in 1.71% of malignant glioma patients with ERBB2 Loss present in 0.08% of all malignant glioma patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 5.44% of malignant solid tumor patients with ERBB2 Loss present in 0.03% of all malignant solid tumor patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 1.22% of astrocytoma patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 1.09% of medulloblastoma patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 2.4% of neuroblastoma patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 2.37% of primitive neuroectodermal tumor patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 0.98% of rhabdomyosarcoma patients [4].

ERBB2 Loss is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].